Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | PYGL | P06737 | 3/20 | 0.33 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.33 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.33 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.33 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | ITGAV | P06756 | 1/20 | 0.33 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 7/20 | 0.32 |
| ▸ | CTSL | P07711 | 5/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25599095 | 0.92 | ACACB (0.34) | ACACBITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL25599298 | 0.89 | CXCR2 (0.35) | PYGLITGB1FNTAFNTB | |
| SCHEMBL25599395 | 0.85 | ACACB (0.32) | ACACBITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL25599311 | 0.85 | ITGB3 (0.32) | ACACBITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL25599307 | 0.85 | ITGB1 (0.34) | ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL25599487 | 0.84 | GPR132 (0.34) | ITGB3ITGB1ITGAVITGA5CTSS | |
| SCHEMBL25599317 | 0.83 | CXCR2 (0.37) | ITGB3ITGB1ITGAVITGA5FNTA | |
| SCHEMBL25599025 | 0.83 | ITGAV (0.38) | PYGLITGAVFNTAFNTB | |
| SCHEMBL23461052 | 0.80 | CNR2 (0.41) | ACACBPYGLGUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL23461054 | 0.80 | CNR2 (0.41) | ACACBPYGLGUCY1B2GUCY1A2GUCY1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159439-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159439-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | ACACB 1130/4885PYGL 1117/4885GUCY1B2 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.